海角视频

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Manufacturing

Covid-19 vaccine maker AstraZeneca's half-year sales surge

The group recently completed a £27.5bn deal for Alexion

A general view of buildings and signage at the Macclesfield Campus of pharmaceutical company AstraZenica (Image: Getty Images)

Covid-19 vaccine maker AstraZeneca's sales surged in the six months before its £27.5bn deal to acquire American drug company Alexion was completed, new figures have revealed.

The group, which developed the vaccine with Oxford University, has reported a total revenue of $15.5bn for the first half of 2021, a rise of 23%.

Its revenue, excluding the Covid-19 vaccine, also increased 14% to $14.3bn.

READ MORE: Historic mills to make way for hundreds of homes as plans given green light

The firm, whose sites are spread across Cheshire, Cambridge and Bedfordshire, also saw a growth in oncology of 19% to $6.3bn and respiratory and immunology rose 11% to $2.9bn.

There was also an increase in emerging markets of 26% to $5.4bn.

Chief executive Pascal Soriot said: "AstraZeneca has delivered another period of strong growth thanks to robust performances across all regions and disease areas, particularly Oncology, New CVRM and Fasenra in Respiratory.